CZ74797A3 - Composition for specific intracellular introduction of a chemical agent and method of such introduction - Google Patents

Composition for specific intracellular introduction of a chemical agent and method of such introduction Download PDF

Info

Publication number
CZ74797A3
CZ74797A3 CZ97747A CZ74797A CZ74797A3 CZ 74797 A3 CZ74797 A3 CZ 74797A3 CZ 97747 A CZ97747 A CZ 97747A CZ 74797 A CZ74797 A CZ 74797A CZ 74797 A3 CZ74797 A3 CZ 74797A3
Authority
CZ
Czechia
Prior art keywords
seq
receptor
ligand
composition
cells
Prior art date
Application number
CZ97747A
Other languages
Czech (cs)
English (en)
Inventor
Ramesh K Prakash
Original Assignee
Theratech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech filed Critical Theratech
Publication of CZ74797A3 publication Critical patent/CZ74797A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ97747A 1994-09-13 1995-09-12 Composition for specific intracellular introduction of a chemical agent and method of such introduction CZ74797A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30577094A 1994-09-13 1994-09-13
PCT/US1995/011515 WO1996008263A1 (en) 1994-09-13 1995-09-12 Intracellular delivery of chemical agents to a specific cell type

Publications (1)

Publication Number Publication Date
CZ74797A3 true CZ74797A3 (en) 1997-08-13

Family

ID=23182273

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ97747A CZ74797A3 (en) 1994-09-13 1995-09-12 Composition for specific intracellular introduction of a chemical agent and method of such introduction

Country Status (13)

Country Link
EP (1) EP0781139A1 (ko)
JP (1) JPH10505835A (ko)
KR (1) KR970705404A (ko)
CN (1) CN1157570A (ko)
AU (1) AU697469B2 (ko)
BR (1) BR9508951A (ko)
CA (1) CA2198361A1 (ko)
CZ (1) CZ74797A3 (ko)
HU (1) HUT77263A (ko)
MX (1) MX9701860A (ko)
PL (1) PL319100A1 (ko)
WO (1) WO1996008263A1 (ko)
ZA (1) ZA957688B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
JP2003516305A (ja) * 1997-08-05 2003-05-13 ワトソン ファーマシューティカルズ， インコーポレイテッド インターロイキン−２レセプターに標的化された結合体
CN1191094C (zh) * 1997-11-19 2005-03-02 乔治敦大学 定向脂质体基因送递
DE19926154A1 (de) * 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease

Also Published As

Publication number Publication date
CA2198361A1 (en) 1996-03-21
AU3550795A (en) 1996-03-29
MX9701860A (es) 1997-06-28
JPH10505835A (ja) 1998-06-09
HUT77263A (hu) 1998-03-02
ZA957688B (en) 1996-05-13
WO1996008263A1 (en) 1996-03-21
PL319100A1 (en) 1997-07-21
KR970705404A (ko) 1997-10-09
BR9508951A (pt) 1999-04-06
AU697469B2 (en) 1998-10-08
CN1157570A (zh) 1997-08-20
EP0781139A1 (en) 1997-07-02

Similar Documents

Publication Publication Date Title
AU695196B2 (en) Nucleic acid transfer system
CA2190494C (en) Heterodimer polypeptide immunogen carrier composition and method
US5428143A (en) Cytotoxic agent against specific virus infection
KR20030025901A (ko) 염증성 반응 억제용 세포 투과성 펩티드 및 사용방법
AU1193999A (en) J-chain and analogues as epithelial cell targeting conjugates
WO2013036973A2 (en) Methods and compositions for controlling assembly of viral proteins
CA2406352A1 (en) Peptide conjugates for drug delivery
WO1996008274A2 (en) Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
JP2001511122A (ja) 新規な上皮組織標的化薬剤
CZ74797A3 (en) Composition for specific intracellular introduction of a chemical agent and method of such introduction
JP2510846B2 (ja) ＰＥ４０Ａｂを含有するタンパク質抗ガン剤
US6770631B1 (en) Non-identical genes and their application in improved molecular adjuvants
MXPA97001860A (en) Intracellular supply of chemical agents, to a specific unit of cel
AU708304B2 (en) Targeting macromolecular prodrugs to T lymphocytes
US5621078A (en) Modified pseudomonas exotoxin PE40
WO2001027144A2 (en) Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
WO1998051336A1 (en) Targeted delivery to t lymphocytes
Riemen et al. Modified pseudomonas exotoxin PE 40
CA2372569A1 (en) Heterodimer polypeptide immunogen carrier composition and method

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic